
The first descriptions of regional citrate anticoagulation (RCA) to maintain circuit patency in continuous kidney replacement therapy (CKRT) were reported 30 years ago.1 More recently, the 2012 Kidney Disease Improving Global Outcomes (KDIGO) acute kidney injury (AKI) guideline advocated for citrate as first-line anticoagulation for CKRT.2 Despite this, there has been relatively modest uptake of citrate anticoagulation, and heparin continues to be the most commonly used anticoagulant for CKRT.3
Like
Save
Share